ArticleClinical pharmacology and therapeutics2011
The impact of pharmacogenomics on the management of cardiac disease.
Article in Clinical pharmacology and therapeutics, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Review
- Point of care CYP2C19 genotyping after percutaneous coronary intervention.The pharmacogenomics journal · 2022Review
- Genotype-based clinical trials in cardiovascular disease.Nature reviews. Cardiology · 2015Review
- Preemptive clinical pharmacogenetics implementation: current programs in five US medical centers.Annual review of pharmacology and toxicology · 2015Review
- Contemporary strategies in the diagnosis and management of heart failure.Mayo Clinic proceedings · 2014Review
- Challenges in implementing genomic medicine: the Mayo Clinic Center for Individualized Medicine.Clinical pharmacology and therapeutics · 2013Article
- Individualized risk for statin-induced myopathy: current knowledge, emerging challenges and potential solutions.Pharmacogenomics · 2012Review
Corrections and comments
- Comment on
Authors and funding
2 authors.
Funding
Abstract
Pharmacogenomics promises to help maximize efficacy and minimize adverse drug reactions. It could have a significant impact on the treatment of cardiovascular disease, the leading cause of death in the United States. The past decade has seen pharmacogenomics move from study of a candidate gene to genome-wide approaches, with the development of a series of pharmacogenetic tests. However, many barriers need to be overcome for cardiovascular pharmacogenomics to have its promised clinical impact.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.